Clinical trials: Graft Loss
Alveolar Bone Loss, Alveolar Ridge Pathology | Gingiva | Dental
Comparative Study of Gene-activated Bone Substitute and Xenogenic Bone Matrix in Alveolar Ridge Augmentation
The study aim is to compare the effectiveness of two bone substitutes, the gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene and xemogenic deproteinized bone matrix, mixed with…
- Trial name
- NCT04511689
- Testing
- gene-activated bone substitute mixed with autobone
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Histograft Co., Ltd.
Alveolar Bone Loss, Periodontal Diseases
GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery
GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.
- Trial name
- NCT01728844
- Testing
- beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Sunstar Americas
Traumatic Encephalopathies, Chronic, Concussion, Mild
Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries
Concussion is the most common type of brain injury throughout life. Study is seeking improvement of long-term residua following adolescent and adult post-traumatic injuries often associated with contact sports and accidental…
- Conditions
- Traumatic Encephalopathies, Chronic, Concussion, Mild, Concussion, Intermediate, Concussion, Severe
- Trial name
- C-TBI (NCT02959294)
- Testing
- Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
- Where
- United States
- Sponsor
- Robert W. Alexander, MD, FICS
Coronary Artery Bypass Graft, Cardiopulmonary Bypass
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
The purpose of this study is to demonstrate that periprocedural infusion of escalating doses of MDCO-2010 is safe and tolerated in patients undergoing elective CABG surgery, to characterize the single dose pharmacokinetics of…
- Trial name
- NCT01535222
- Testing
- MDCO-2010
- Volunteers
- 32 people
- Sponsor
- The Medicines Company
Alveolar Bone Loss
Localized Alveolar Ridge Augmentation With Space Maintenance Devices
The purpose of this research study is to determine whether this study treatment can improve the bone structure of the upper front part of the jaw in patients who are scheduled for surgery to have a dental implant(s) placed into…
- Trial name
- Ridge Mesh (NCT00991432)
- Testing
- INFUSE® Bone Graft
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Medtronic Spinal and Biologics
Bone Fractures, Bone Defects
Study on Safety and Performance of AdvanCore Bone Void Filler
The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and…
- Conditions
- Bone Fractures, Bone Defects, Bone Loss, Bone Graft
- Trial name
- NCT06736457
- Testing
- AdvanCore bone grafting
- Where
- 4 sites in Portugal
- Volunteers
- 190 people
- Sponsor
- Artur Salgado SA
Maxillary Sinus Bone Loss
Sinus Augmentation With Dental Implant
The purpose of this research study is to shorten the treatment time course for patients who are scheduled for surgery to have a sinus lift and dental implant(s) placed into the upper front part of their mouth, and need to have…
- Trial name
- SinusDI (NCT00991393)
- Testing
- INFUSE® Bone Graft
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Medtronic Spinal and Biologics
Oral Surgical Procedures
Retrospective Observational Study of Implant-supported Restorations With Dental Implants.
This retrospective study aims to value the bone loss and the success and survival of the dental implants produced by additive manufacturing installed in an area grafted with Plenum® Osshp (synthetic bone graft).
- Trial name
- NCT06154057
- Testing
- Dental Implants installed in an grafted area (sinus lifting), Dental Implants installed in an grafted area (ridge augmentation), Dental Implants installed in an grafted area (extraction sites)
- Where
- Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- M3 Health
Non Union Fracture, Non-Union of Ankle Joint Without Infection
Comparative Study of Gene-activated Bone Substitute and Autobone in Treatment of Long Bone Nonunions
The study is aimed to compare the effectiveness of "Histograft" bone substitute (gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone and pure shredded…
- Trial name
- NCT04705857
- Testing
- "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Histograft Co., Ltd.
Postoperative Hemorrhage
Aprotinin US Special Access Protocol
This is a special access protocol that will allow physicians access to aprotinin during the temporary marketing suspension. The program will provide aprotinin for treatment of surgical patients undergoing coronary artery bypass…
- Trial name
- NCT00611845
- Testing
- Aprotinin (Trasylol, BAYA0128)
- Where
- 17 sites in United States
- Sponsor
- Bayer
Bloodloss, Surgical Procedures, Operative
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
- Trial name
- CONSERV-1 (NCT00816023)
- Testing
- ecallantide
- Where
- 29 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Graft Rejection
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
- Trial name
- NCT00300274
- Testing
- everolimus, mycophenolate mofetil, cyclosporine
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 721 people
- Sponsor
- Novartis Pharmaceuticals
Nipple Necrosis, Nipple Graft Loss
Plexaa For Preconditioning: Gender Affirming Mastectomy
The goal of this clinical trial is to evaluate the use of the Plexaa preconditioning device (BLOOM43) in transgender and non-binary patients undergoing gender affirming mastectomy.
- Trial name
- P4PGAM (NCT06502353)
- Testing
- BLOOM43
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Plexaa Ltd
Jaw, Edentulous, Partially, Alveolar Bone Loss
Straumann Bone Ceramic Versus BioOss in Sinus Elevation
Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is a need for bone augmentation in the posterior upper jaw. 9 months later the bone formation is evaluated.
- Trial name
- NCT00900822
- Testing
- Straumann Bone Ceramic, BioOss
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Institut Straumann AG
Bone Loss in Jaw
Evaluation of Efficacy and Safety of Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation
Evaluation of efficacy and safety of Wishbone HA as bone graft substitute, a pre-market clinical investigation. Group1: Extraction Socket management Group 2: Sinus lift
- Trial name
- NCT04054219
- Testing
- Bone graft substitute
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wishbone SA
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Alveolar Bone Loss in Mandible, Edentulous Alveolar Ridge In Mandible
Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation
The purpose of this study is to evaluate the INFUSE® Bone Graft as an alternative to autograft for bone formation in the back of the mandible (lower jaw) prior to placing dental implants.
- Trial name
- NCT01308996
- Testing
- INFUSE® Bone Graft, Autogenous bone graft from tibia or iliac crest
- Sponsor
- Medtronic Spinal and Biologics
Teeth Loss, Bone Loss
Maxillary Sinus Elevation With Bio-Oss or Straumann BoneCeramic
The purpose of the study was to test a clinically relevant non-inferiority of Straumann BoneCeramic treatment compared to Bio-Oss treatment 180 to 240 days after sinus grafting procedure.
- Trial name
- NCT00901121
- Testing
- Straumann BoneCeramic, Bio-Oss
- Where
- 8 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Institut Straumann AG
Bone Cysts, Bone Atrophy
Gene-activated Bone Substitute for Maxillofacial Bone Regeneration
The purpose of this study is to evaluate the safety and efficacy of the gene-activated bone substitute consisting of octacalcium phosphate and plasmid DNA encoding vascular endothelial growth factor (VEGF) for maxillofacial bone…
- Conditions
- Bone Cysts, Bone Atrophy, Bone Deformity, Bone Fracture
- Trial name
- NCT03076138
- Testing
- Gene-activated matrix (OCP + plasmid DNA with VEGF gene)
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Histograft Co., Ltd.
Blood Loss, Surgical
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
The primary objective of this study was to assess the efficacy and safety of 2 dose levels of ecallantide versus placebo in reducing blood loss following cardiopulmonary bypass (CPB), as measured by chest tube drainage during the…
- Trial name
- NCT00448864
- Testing
- Ecallantide
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)